Category : Ben Claremon

Reflections from Omaha: A Case of Cognitive Dissonance

by Ben Claremon | Principal, Research Analyst After taking a year off from partaking in the annual trek to Omaha, I returned to the home of The Oracle looking to be re-invigorated. There is so much noise and nonsense that […]

One More Look at Currency

by Ben Claremon | Research Analyst As of the huge currency moves the world has witnessed over the last year or so, the topic of currency hedging has recently become very pertinent to both investors and companies who generate sales […]

Quarterly Earnings: Our Sentiments Exactly!

by Ben Claremon | Research Analyst As long term-focused investors, we have a certain disdain for the quarterly earnings rigmarole and the associated maniacal focus on “beating” what are somewhat irrelevant earnings per share estimates. The truth of the matter […]

Buffett vs. Icahn on Coca Cola? Slam dunk for Icahn.

by Jeff Bronchick and Ben Claremon We have been thinking about this issue for a few weeks, tempering our urge to dash out some heated thoughts of the moment. We have gotten over it. Ignoring for a moment the details […]

The Annual Pilgrimage to Omaha

Berkshire This past weekend’s trek to Omaha for the Berkshire Hathaway annual meeting represented the fifth consecutive time I have ventured to see the Oracle of Omaha and the man they call Charlie share their wisdom. Sorry folks, I didn’t […]

Ben Claremon and the Great White North

Under normal circumstances, the prospect of leaving sunny Southern California to travel to a place where the day-time temperature encourages the wearing of fur is not particularly appealing. But I decided this year to make the slog to attend Fairfax […]

Hello Ruby Tuesday

A few weeks ago, Cove Street was asked to present a small cap stock idea for the 2013 Small-Cap Investing Summit. Our analyst Ben Claremon chose to discuss the investment thesis for Ruby Tuesday (RT) and created the attached presentation. Despite […]

The Next Generation: An Interview with Ben Claremon & Eugene Robin

CSC research analysts and blog contributors Ben Claremon and Eugene Robin were recently interviewed for The Wall Street Transcript. CLICK HERE to download the article.  

Inoculation 2012: The Berkshire Hathaway Meeting

 Dear Value Investors, This was my fourth trip to the so-called Woodstock for Value Investors and my latest attempt to capture the majority of the comments made by Warren Buffett and Charlie Munger. Over that time, what hasn’t materially […]

Notes from the Front Line: UCLA

The opinions expressed herein are not those of Cove Street Capital. The post was written by Ben Claremon, an employee of CSC, and includes his summaries of speeches given at a recent UCLA Anderson Investment Association Conference. You should not consider […]

In Support the of Home Team

by Ben Claremon It was less than two years ago that I was sitting with some of my UCLA Anderson classmates, desperately trying to figure out what to do for our Applied Management Research or AMR project. Most students fulfill […]

Warren and Ben


Earnings Per Share Myopia

By Ben Claremon Welcome to earnings season and the barrage of company press releases and conference calls. Securities analysts all over the country currently have their noses buried in 8-K’s and 10-Q’s, hoping to get a sense of company-specific and […]

In a Zero Hedge World, Investors Must Stay Nimble

by Ben Claremon All European banks are insolvent! Germany is going to leave the Euro! The US is going to default on its debt obligations! Any investor who has spent time trolling the internet—especially the blogosphere—or listening to talking heads […]

Do I Detect a Hint of Optimism?

To counter the rumor that I am incapable of ceding the pen, I present Ben Claremon, Cove Street analyst, aka The Inoculated Investor.  – Jeffrey Bronchick, CFA   ——Do I Detect a Hint of Optimism?————————————————————– By Ben Claremon I am […]